Liquidia Technologies Inc (LQDA)vsUnited Therapeutics Corporation (UTHR)
LQDA
Liquidia Technologies Inc
$68.64
+3.33%
HEALTHCARE · Cap: $5.95B
UTHR
United Therapeutics Corporation
$497.59
+0.91%
HEALTHCARE · Cap: $21.22B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 600% more annual revenue ($3.15B vs $450.91M). UTHR leads profitability with a 41.6% profit margin vs 30.7%. UTHR trades at a lower P/E of 17.7x. UTHR earns a higher WallStSmart Score of 61/100 (C+).
LQDA
Buy60
out of 100
Grade: C
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
+0.8%
Fair Value
$479.67
Current Price
$497.59
$17.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 31.3x book value
Distress zone — elevated risk
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, P/E Ratio, Price/Book. A P/E of 47.5x leaves little room for execution misses.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
LQDA profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.56 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 60/100), backed by strong 41.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?